Radiopharm Theranostics' RAD101 Hits Primary Endpoint in Phase 2b Trial for Brain Metastases Diagnosis
Event summary
- RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint.
- Preliminary sensitivity of RAD101 was 86% (12/14) in patients with six-month follow-up or biopsy data.
- Radiopharm plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026.
- The imaging brain metastases market is estimated at $600M+ with no currently approved PET product.
The big picture
Radiopharm Theranostics' positive Phase 2b trial results for RAD101 address a critical diagnostic gap in neuro-oncology, where CE-MRI has limitations. The company is positioning itself to capitalize on the growing incidence of intracranial metastatic disease, with over 300,000 patients diagnosed annually in the U.S. alone. The strategic partnership with Siemens Healthineers underscores the potential scalability of RAD101's commercialization.
What we're watching
- Regulatory Pathway
- Whether the FDA Fast Track Designation will expedite RAD101's approval process and support its Phase 3 trial initiation.
- Market Opportunity
- The pace at which Radiopharm can capture the $600M+ imaging brain metastases market with RAD101.
- Partnership Dynamics
- How Siemens Healthineers' manufacturing and distribution support will impact RAD101's commercialization strategy.
Related topics